Literature DB >> 18508458

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism.

John D Salamone1, Adrienne J Betz, Keita Ishiwari, Jennifer Felsted, Lisa Madson, Brian Mirante, Karen Clark, Laura Font, Samantha Korbey, Thomas N Sager, Jorg Hockemeyer, Christa E Muller.   

Abstract

Drug-induced tremulous jaw movements in rats have been used as a model of parkinsonian tremor. Because adenosine A2A antagonists have antiparkinsonian effects, the present experiments were conducted to study the ability of adenosine A2A antagonism to reverse the tremulous jaw movements produced by the antipsychotic drugs pimozide, haloperidol and reserpine. In one group of studies, rats received daily injections of the dopamine antagonist pimozide, and on day 8 they received injections of pimozide plus various doses of the A2A antagonists KW 6002 or MSX-3. KW 6002 and MSX-3 suppressed pimozide-induced tremulous jaw movements, reduced catalepsy, and increased locomotion. MSX-3 also suppressed the jaw movements induced by haloperidol and reserpine. In addition, local injections of MSX-3 into the ventrolateral neostriatum suppressed pimozide-induced tremulous jaw movements. Thus, adenosine A2A antagonism can reverse the tremulous movements induced by antipsychotic drugs, which is consistent with the hypothesis that antagonism of adenosine A2A receptors can result in antiparkinsonian effects. Adenosine A2A antagonists may be useful for their tremorolytic effects, and may help in treating both idiopathic and antipsychotic-induced parkinsonian symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508458     DOI: 10.2741/2952

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  26 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

Review 2.  Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.

Authors:  Annalisa Pinna
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

Review 3.  The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.

Authors:  John D Salamone; Merce Correa; Eric J Nunes; Patrick A Randall; Marta Pardo
Journal:  J Exp Anal Behav       Date:  2012-01       Impact factor: 2.468

4.  Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.

Authors:  John D Salamone; Andrew M Farrar; Laura Font; Vatsal Patel; Devra E Schlar; Eric J Nunes; Lyndsey E Collins; Thomas N Sager
Journal:  Behav Brain Res       Date:  2009-03-03       Impact factor: 3.332

5.  The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists.

Authors:  Lila T Worden; Mona Shahriari; Andrew M Farrar; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2008-12-02       Impact factor: 4.530

6.  A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Authors:  Kimberly E Vanover; Adrienne J Betz; Suzanne M Weber; Francesco Bibbiani; Aiste Kielaite; David M Weiner; Robert E Davis; Thomas N Chase; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

Review 7.  Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

Authors:  Marie Therese Armentero; Annalisa Pinna; Sergi Ferré; José Luis Lanciego; Christa E Müller; Rafael Franco
Journal:  Pharmacol Ther       Date:  2011-07-23       Impact factor: 12.310

Review 8.  A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.

Authors:  Annalisa Pinna; Micaela Morelli
Journal:  Neurotox Res       Date:  2013-12-10       Impact factor: 3.911

Review 9.  Role of adenosine A2A receptors in motor control: relevance to Parkinson's disease and dyskinesia.

Authors:  Annalisa Pinna; Marcello Serra; Micaela Morelli; Nicola Simola
Journal:  J Neural Transm (Vienna)       Date:  2018-02-02       Impact factor: 3.575

10.  Dopamine, behavioral economics, and effort.

Authors:  John D Salamone; Merce Correa; Andrew M Farrar; Eric J Nunes; Marta Pardo
Journal:  Front Behav Neurosci       Date:  2009-09-07       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.